Recursion Pharmaceuticals stock reached a key performance benchmark, with its Relative Strength (RS) Rating rising into the ...

Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 11.8% in the morning session after it continued to build on the ...

Septerna stood out from the crowd of biotech IPOs last year due to the lack of clinical data to hand. Now, the data are ...

Stoke Therapeutics Inc. (Nasdaq: STOK) has pulled in Biogen (Nasdaq: BIIB) to help it develop and commercialize a treatment ...

GeneDx stock catapulted Tuesday after the top-notch biotech smashed fourth-quarter expectations and issued upbeat guidance.

The reelection of former President Donald Trump initially pleased investors who had worried about another protracted legal ...

Compugen's innovative approach targets under-explored immune pathways like PVRIG and IL-18 binding protein. Read why I'm ...

The deal, which features up to $385 million in milestones, gives Biogen exclusive rights to commercialize Stoke’s ...

Additional information about the reverse stock split can be found in the Current Report on Form 8-K filed today and in the Company's definitive proxy statement (Form DEF 14A) filed with the United ...

Biogen and Stoke partner on zorevunersen for Dravet syndrome, with a Phase 3 trial starting in 2025. Stoke gets $165 million ...

A total of 66 companies have submitted applications for IPOs, with highly anticipated offerings from Hero Fincorp and LG ...